OBI Pharma
Thomas Huang is an accomplished IT professional with extensive experience in cybersecurity, strategy planning, and operations management. Currently serving as the Head of IT at OBI Pharma, Inc. since August 2021, Thomas leads the IT department in developing novel therapeutic agents for unmet medical needs. Previous roles include Senior Director at SYSTEX, where cybersecurity consulting was a key focus, and Lead Auditor at SGS, conducting IT cybersecurity certification audits. Additional experience includes strategic roles in Pou Chen Group and Apache Footwear, business development at General Atomics, and consulting at Hewlett-Packard, along with a foundational position in education at Taipei Municipal Huajiang Senior School. Thomas holds multiple degrees, including a Doctor's Degree in Applied Mathematics from National Chung Hsing University and an MBA from the University of California, San Diego.
This person is not in any teams
This person is not in any offices
OBI Pharma
OBI Pharma Inc. (OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by Dr. Michael Chang, an accomplished biotech entrepreneur in the United States. Its stocks were issued publicly in 2012. Subsequently, the company was successfully listed on the Taipei Exchange (4174.TWO) in 2015. OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs worldwide with a “Made in Taiwan” branding and to provide new treatment options for patients with unmet medical needs. The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADC) drugs for patients, in addition to its promising Globo series (e.g., Globo H) of cancer therapeutic vaccines. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin4, HER2, etc. These ADCs are built based on two distinct ADC technology platforms, each with different characteristics. Both platforms are customizable and offer a “plug-and-play” advantage through a specialized site-specific conjugation using a proprietary enzyme. With the added value of scalability, these “plug-and-play” technology platforms enable ADC development to be relatively simple and efficient. OBI is interested in commercializing its ADC technology platforms and looks forward to collaborating with biotech and pharmaceutical companies by enabling “first-in-class” and “best-in-class” therapeutic candidates for further development.